SAVA Jan 2024 40.000 call
| Previous Close | 0.4000 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 40.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 0.4000 - 0.4000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GlobeNewswireCassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials.The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification AUSTIN, Texas, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced a positive interim safety review of simufilam in on-going Phase 3 clinical trials in
- GlobeNewswire
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once again confirm the biological activity of simufilam. AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam. Simuf
- GlobeNewswire
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences. Event:Morgan Stanley - 21stAnnual Global Healthcare ConferenceFormat:Fireside chat with Remi Barbier, President & CEODate:Monday, September 11, 2023Where:New York City Event:H.C. Wainwright - 25thAnnual Global Investment ConferenceForma
